#Vienna #Austria #RNA Therapy #Lexogen #Ochre Bio

Lexogen Completes Successful Next-Generation Sequencing Project with Ochre Bio

On November 25, 2025, Lexogen, a biotech firm based in Vienna, announced the successful completion of a significant data generation project associated with human primary cells in collaboration with Ochre Bio. This ambitious project was focused on producing extensive functional genomic datasets from primary human hepatocytes, utilizing Lexogen's proprietary extraction-free, high-resolution gene expression profiling platform and advanced next-generation sequencing (NGS) services.

The initiative involved analyzing more than 120,000 samples, showcasing Lexogen's expertise in RNA transcriptomics. Ochre Bio, known for developing RNA-based medicines for underserved chronic liver conditions, leverages these genomic datasets to create integrated human liver atlases, aiding in predicting causal pathways for target identification and the development of RNA therapies. Key to their success is Ochre's proprietary software, OBELiX, which enables detailed analysis of gene biology across human cells and tissues, providing an AI-driven discovery engine that prioritizes target molecules effectively.

The high-accuracy RNA-seq datasets generated through this collaboration are crucial for Ochre's platform in identifying new target molecules. Lexogen has established itself as a trusted sequencing partner for Ochre Bio by consistently delivering high-quality RNA-seq data from various sample types, including FFPE samples from biobanks and large-scale primary hepatocyte samples, all within deadlines. Lexogen's NGS services adhere to cGLP regulations and are centered around its own technologies designed, developed, and manufactured under ISO 13485 standards in Vienna, Austria. This positions them uniquely to provide state-of-the-art, optimized, and customizable workflows, ensuring optimal results even from the most challenging sample types.

Quin Wills, the founder and CEO of Ochre Bio, highlighted the significance of data quality in AI-powered target identification: "A platform is only as powerful as the data that fuels it. With over 120,000 samples from primary human hepatocytes, a naturally complex and variable system, strict data quality and inter-sample consistency are crucial for interpretability. Accurate sequencing data, standardized processing, and reproducible assay performance enable machine learning models to distinguish real biological signals from technical noise. Lexogen’s proprietary THOR technology and their professional RNA-seq service have delivered high-quality large-scale data, laying the foundation for improved target predictions in the future."

Stephane Barges, CEO of Lexogen, emphasized the commitment to high-quality service: "Lexogen is dedicated to providing dependable, accurate data to our clients and industry partners. Delivering reliable results is at the core of our operations, and we strive to meet the highest standards throughout the process. By focusing on quality and consistency, we aim to support our partners in advancing their discoveries and accelerating innovation. Our mission goes even further; we are deeply motivated to assist researchers and enterprises developing therapies and diagnostic tools that enhance patient lives, and we are grateful that our work contributes to better healthcare for all."

With nearly two decades of experience, Lexogen provides comprehensive solutions for transcriptome analysis and RNA sequencing, encompassing kits, reagents, bioinformatics, and contract research organization (CRO) services. The company develops and manufactures its products in Vienna, Austria, with sequencing services delivered from the same location. Lexogen is certified under ISO 9001 and ISO 1385, ensuring that all services comply with cGLP and privacy regulations.

To learn more, visit Lexogen's website at www.lexogen.com and follow them on social media @lexogen.